These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 37188188)
1. PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report. Yang J; Xing P; Kong Y; Xu M; Zhang L Front Oncol; 2023; 13():1078915. PubMed ID: 37188188 [TBL] [Abstract][Full Text] [Related]
2. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study. Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009 [No Abstract] [Full Text] [Related]
3. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. Liu X; Yao J; Song L; Zhang S; Huang T; Li Y J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer. Ding Y; Weng S; Zhu N; Mi M; Xu Z; Zhong L; Yuan Y Heliyon; 2023 Nov; 9(11):e22092. PubMed ID: 38058653 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study. Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046 [TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade combined with chemotherapy and bevacizumab in DNA mismatch repair-proficient/microsatellite stable colorectal liver metastases. Men Q; Duan Y; Pei F; Yao Q; He W; Zhao Y; Shi L; Liu G; Huang J J Gastrointest Oncol; 2024 Aug; 15(4):1534-1544. PubMed ID: 39279968 [TBL] [Abstract][Full Text] [Related]
7. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report. He L; Cheng X; Zhou C; Li Q; Zhang B; Cheng X; Donadon M; Mannavola F; Tu S J Gastrointest Oncol; 2023 Dec; 14(6):2617-2626. PubMed ID: 38196522 [TBL] [Abstract][Full Text] [Related]
8. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ. Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072 [TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report. Cheng X; Li X; Yang X; Fang S; Wang Z; Liu T; Zheng M; Zhai M; Yang Z; Shen T Cureus; 2023 Jul; 15(7):e42347. PubMed ID: 37621810 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer: a retrospective single-arm cohort study. Li RR; Yin XL; Zeng DY; Shao FJ; Yamamoto S; Liu W; Liu ZY Ann Transl Med; 2022 Aug; 10(16):880. PubMed ID: 36111036 [TBL] [Abstract][Full Text] [Related]
11. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of radiotherapy combined with anti-angiogenic therapy and immune checkpoint inhibitors in MSS/pMMR metastatic colorectal cancer. Zhai M; Zhang Z; Wang H; Ren J; Zhang S; Li M; Liu L; Li L; Zhang L; Li X; Zhang T; Lin Z Cancer Med; 2024 Jan; 13(1):e6820. PubMed ID: 38112050 [TBL] [Abstract][Full Text] [Related]
13. Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report. Liu Y; Du J; Zhang P; Meng W; Xiao H Front Oncol; 2023; 13():1051786. PubMed ID: 36969074 [TBL] [Abstract][Full Text] [Related]
14. Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor. Song Y; Long J; Su X; Chen Z; He Y; Shao W; Wang B; Chen C Front Immunol; 2023; 14():1197543. PubMed ID: 37520536 [TBL] [Abstract][Full Text] [Related]
16. The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study. Li J; Cong L; Liu J; Peng L; Wang J; Feng A; Yue J; Li L; Wang X; Wang X Front Oncol; 2020; 10():594125. PubMed ID: 33282742 [TBL] [Abstract][Full Text] [Related]
17. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer]. Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171 [No Abstract] [Full Text] [Related]
18. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer. Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. Sun L; Huang S; Li D; Mao Y; Wang Y; Wu J Front Oncol; 2021; 11():754881. PubMed ID: 34692541 [TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials. Germani MM; Moretto R Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]